MedTrace Logo

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

NCT03713944 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-01

Study results available
· View outcomes & findings →

Summary

This is a multicenter single arm phase II clinical trial. All eligible patients will receive:

Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.

Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities.

Conditions

  • NSCLC Stage IV
  • NSCLC, Recurrent

Interventions

DRUG

Carboplatin

Carboplatin, AUC 5

DRUG

Pemetrexed

Pemetrexed 500mg/m2

DRUG

Atezolizumab

Atezolizumab 1200mg

DRUG

Bevacizumab

Bevacizumab 15mg/kg

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Nasser Hanna

    lead OTHER

Principal Investigators

  • Nasser Hanna, MD · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2021-12-16
Completion
2021-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713944 on ClinicalTrials.gov